Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, Germany, Hongkong, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.13
AMGN's Cash-to-Debt is ranked lower than
80% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. AMGN: 1.13 )
Ranked among companies with meaningful Cash-to-Debt only.
AMGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 1.02 Max: N/A
Current: 1.13
Equity-to-Asset 0.39
AMGN's Equity-to-Asset is ranked lower than
79% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMGN: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
AMGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.64 Max: 0.85
Current: 0.39
0.33
0.85
Interest Coverage 16.15
AMGN's Interest Coverage is ranked lower than
83% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMGN: 16.15 )
Ranked among companies with meaningful Interest Coverage only.
AMGN' s Interest Coverage Range Over the Past 10 Years
Min: 5.3  Med: 9.32 Max: 15.52
Current: 16.15
5.3
15.52
Piotroski F-Score: 7
Altman Z-Score: 2.96
Beneish M-Score: -2.63
WACC vs ROIC
10.60%
30.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 43.54
AMGN's Operating Margin % is ranked higher than
96% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. AMGN: 43.54 )
Ranked among companies with meaningful Operating Margin % only.
AMGN' s Operating Margin % Range Over the Past 10 Years
Min: 26.94  Med: 33.53 Max: 42.6
Current: 43.54
26.94
42.6
Net Margin % 34.43
AMGN's Net Margin % is ranked higher than
94% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. AMGN: 34.43 )
Ranked among companies with meaningful Net Margin % only.
AMGN' s Net Margin % Range Over the Past 10 Years
Min: 21.43  Med: 27.11 Max: 33.59
Current: 34.43
21.43
33.59
ROE % 26.29
AMGN's ROE % is ranked higher than
96% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. AMGN: 26.29 )
Ranked among companies with meaningful ROE % only.
AMGN' s ROE % Range Over the Past 10 Years
Min: 17.14  Med: 21.47 Max: 26.65
Current: 26.29
17.14
26.65
ROA % 10.27
AMGN's ROA % is ranked higher than
91% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. AMGN: 10.27 )
Ranked among companies with meaningful ROA % only.
AMGN' s ROA % Range Over the Past 10 Years
Min: 7.63  Med: 9.57 Max: 12.11
Current: 10.27
7.63
12.11
ROC (Joel Greenblatt) % 152.43
AMGN's ROC (Joel Greenblatt) % is ranked higher than
95% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. AMGN: 152.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 61.87  Med: 82.2 Max: 167.3
Current: 152.43
61.87
167.3
3-Year Revenue Growth Rate 7.70
AMGN's 3-Year Revenue Growth Rate is ranked higher than
56% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AMGN: 7.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.8  Med: 16.1 Max: 121.7
Current: 7.7
5.8
121.7
3-Year EBITDA Growth Rate 16.80
AMGN's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. AMGN: 16.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 16.8 Max: 702.6
Current: 16.8
-1.6
702.6
3-Year EPS without NRI Growth Rate 15.50
AMGN's 3-Year EPS without NRI Growth Rate is ranked higher than
70% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. AMGN: 15.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 2.3  Med: 18.7 Max: 124.6
Current: 15.5
2.3
124.6
GuruFocus has detected 2 Warning Signs with Amgen Inc $AMGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMGN's 30-Y Financials

Financials (Next Earnings Date: 2017-07-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AMGN Guru Trades in Q3 2016

George Soros 3,506 sh (New)
Richard Pzena 1,196 sh (New)
Paul Tudor Jones 21,333 sh (+276.31%)
Jim Simons 1,896,341 sh (+61.19%)
Ken Fisher 102,794 sh (+1.20%)
Keeley Asset Management Corp 1,325 sh (unchged)
John Hussman 900 sh (unchged)
Mairs and Power 9,916 sh (unchged)
David Carlson 460,000 sh (unchged)
Ray Dalio Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Third Avenue Management 134,226 sh (-1.04%)
John Buckingham 55,692 sh (-1.22%)
Manning & Napier Advisors, Inc 68,495 sh (-1.81%)
Dodge & Cox 40,157 sh (-2.67%)
PRIMECAP Management 26,560,551 sh (-7.24%)
Lee Ainslie 3,630 sh (-7.87%)
Jeremy Grantham 2,399 sh (-14.29%)
Mario Gabelli 22,425 sh (-38.27%)
Joel Greenblatt 269,204 sh (-44.60%)
Vanguard Health Care Fund 2,759,552 sh (-46.83%)
First Eagle Investment 369,976 sh (-60.50%)
Pioneer Investments 1,554 sh (-98.77%)
» More
Q4 2016

AMGN Guru Trades in Q4 2016

David Dreman 1,114 sh (New)
Richard Snow 15,954 sh (New)
Third Avenue Management 210,262 sh (+56.65%)
Lee Ainslie 4,570 sh (+25.90%)
Ken Fisher 123,139 sh (+19.79%)
Joel Greenblatt 311,380 sh (+15.67%)
Richard Pzena 1,372 sh (+14.72%)
Pioneer Investments 1,767 sh (+13.71%)
Jeremy Grantham 2,499 sh (+4.17%)
Manning & Napier Advisors, Inc 71,003 sh (+3.66%)
John Buckingham 55,900 sh (+0.37%)
Martin Whitman 139,400 sh (+14.92%)
Mairs and Power 9,916 sh (unchged)
David Carlson 460,000 sh (unchged)
George Soros Sold Out
Keeley Asset Management Corp Sold Out
First Eagle Investment Sold Out
John Hussman Sold Out
Mario Gabelli 22,020 sh (-1.81%)
Dodge & Cox 39,207 sh (-2.37%)
PRIMECAP Management 24,999,391 sh (-5.88%)
Jim Simons 1,778,645 sh (-6.21%)
Vanguard Health Care Fund 1,845,162 sh (-33.14%)
Paul Tudor Jones 3,700 sh (-82.66%)
» More
Q1 2017

AMGN Guru Trades in Q1 2017

George Soros 2,000 sh (New)
Barrow, Hanley, Mewhinney & Strauss 248 sh (New)
Jeff Auxier 1,300 sh (New)
Steven Cohen 180,000 sh (New)
Caxton Associates 2,500 sh (New)
Ray Dalio 51,460 sh (New)
Pioneer Investments 91,276 sh (+5065.59%)
Richard Snow 52,001 sh (+225.94%)
Paul Tudor Jones 7,832 sh (+111.68%)
Jim Simons 2,413,445 sh (+35.69%)
Joel Greenblatt 397,344 sh (+27.61%)
Manning & Napier Advisors, Inc 74,381 sh (+4.76%)
John Buckingham 56,326 sh (+0.76%)
Third Avenue Management 211,084 sh (+0.39%)
Martin Whitman 176,500 sh (+26.61%)
Steven Cohen 298,500 sh (unchged)
David Carlson 460,000 sh (unchged)
David Dreman Sold Out
Ken Fisher 123,020 sh (-0.10%)
PRIMECAP Management 24,105,794 sh (-3.57%)
Mario Gabelli 21,024 sh (-4.52%)
Richard Pzena 1,297 sh (-5.47%)
Mairs and Power 8,845 sh (-10.80%)
Lee Ainslie 3,780 sh (-17.29%)
Dodge & Cox 32,137 sh (-18.03%)
Jeremy Grantham 2,000 sh (-19.97%)
Vanguard Health Care Fund 526,472 sh (-71.47%)
» More
Q2 2017

AMGN Guru Trades in Q2 2017

Manning & Napier Advisors, Inc 115,170 sh (+54.84%)
Ken Fisher 126,537 sh (+2.86%)
Martin Whitman 176,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:AMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CELG, NAS:GILD, NAS:BIIB, NAS:REGN, NAS:VRTX, NAS:ALXN, NAS:INCY, NAS:BMRN, NAS:EXEL, NAS:SGEN, NAS:TSRO, NAS:ALNY, NAS:BIVV, NAS:IONS, NAS:UTHR, NAS:KITE, NAS:CLVS, NAS:TECH, NAS:NBIX, NAS:BLUE » details
Traded in other countries:AMGN.Argentina, AMGN.Austria, AMGN34.Brazil, AMGN.Chile, AMG.Germany, 04332.Hongkong, AMG N.Mexico, AMGN.Switzerland, 0R0T.UK,
Headquarter Location:USA
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. The Company's business segment is human therapeutics.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolsters the firm's therapeutic oncology portfolio with Nexavar and Kyprolis.

Guru Investment Theses on Amgen Inc

Third Avenue Fund Comments on Amgen - Sep 14, 2016

Livallova

Investor neglect can be a source of new ideas while also providing an element of downside protection. We found this combination to be compelling in our purchase of Livallova (NASDAQ:LIVN), which is the new name for Sorin and Cyberonics post their late-2015 merger. We think investor neglect was paramount, for Sorin, an Italian company, which merged with Cyberonics, based in Houston, changed its name and reincorporated in London. Indeed, we came across the company on a screen of our potential universe of companies, and had to do some digging into the new name we did not recognize, to realize the potential for these two well-known companies and the significant potential their merger offers.

Livallova is a healthcare company with a $3 billion market capitalization that holds leading positions in cardiac surgical equipment, surgical heart valve replacement, neuromodulation and cardiac rhythm management. In its cardiac surgery division, Livallova holds number one positions in Oxygenators and Heart Lung machines. It also is rapidly gaining share with its new sutureless Perceval heart valve, with a history of successful procedures in Europe and recently approved in the U.S. In Neuromodulation, Livallova holds the number one position in devices for the treatment of drug resistant epilepsy, led by its success with its AspireSR device. Livallova is also rapidly gaining share in cardiac rhythm management with Kora250 and Platinium in Japan and Europe, while retaining options on strategies to re-enter the U.S. market. In all, Livallova holds number one positions in over 60% of its revenues.

Livallova also has a strong self-help profile, with targeted synergies from its merger of $80 million over three years. As of its second quarter earnings call, Livallova indicated it was ahead of the first phase of $19 million expected in 2016. Creditworthiness for the company is easily demonstrated by net debt of roughly $75 million.

The ability to compound earnings and book value growth is not only supported by its new product introductions and merger synergies, but also its compelling research and development pipeline, which Livallova refers to as its New Ventures unit. In this unit, Livallova is pursuing groundbreaking new technologies in percutaneous mitral valve repair and replacement, the adaption of its Neuromodulation technologies for treatment of central and obstructive sleep apnea and also the potential to treat heart failure through vagus nerve stimulation. Not only is the potential market opportunity for all three of these areas separately in excess of a billion dollars, but through its merger, Livallova has multiple research efforts in each area to evaluate, streamline and prioritize.

Brexit created a window to initiate a position at under $50 per share for the Fund, which represents a compelling 50% upside to our fair value NAV target. Perhaps due to investor neglect on the name, Livallova trades at a substantial discount to its U.S. peers. We think this discount and its relatively smaller market capitalization also provide downside protection, for the company would likely be attractive to a larger entity looking to expand its product franchise.



From Third Avenue Value Fund's third quarter 2016 letter.



Check out Third Avenue Management,Martin Whitman latest stock trades

Third Avenue Fund Comments on Amgen - Sep 14, 2016

Amgen (NASDAQ:AMGN), which was founded in 1980, is one of the world's leading biotechnology companies. Interestingly, the biotech industry has matured over the years and some of the companies generate stable cash flows, not unlike some of the larger pharmaceutical companies. Amgen is one of these. Competitive issues, largely surrounding the biosimilar debate, have put pressure on Amgen's stock. Post-Brexit market volatility provided us an opportunity to acquire shares.

Amgen has a diversified product portfolio across six therapeutic areas: oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its key products are Enbrel for long-term inflammatory diseases such as rheumatoid arthritis; Epogen and Aranesp for anemia; Neupogen and Neulasta for treating neutropenia (a lack of certain white blood cells caused by cancer, bone marrow transplant, or after chemotherapy). Newer drugs include Repatha, which targets high cholesterol for the roughly 20% of the population who are intolerant of statins (the typical first line treatment), and Kyprolis for multiple myeloma, an incurable bone cancer. Its pipeline consists of 31

preclinical and clinical targets, 12 of which are in the later stages. Amgen also has a pipeline of 9 biosimilars, of which 3 are in late stage and for which the worldwide sales of the originator drugs totaled approximately $54 billion in 2015.

The company generated $9 billion in operating cash flow in 2015, up from $5.1 billion in 2011. The company has used its excess cash flow to fund growth as well as return cash to shareholders via both share buybacks and dividends. It expects to return 60% of adjusted net income to shareholders by 2018.

Amgen has longer-term opportunities for margin improvement from synergies and cost controls. The company initiated a large-scale "transformation" program in 2013 to focus on efficient allocation of resources. The plan included an approximately 23% reduction in its facilities footprint and a 20% reduction in headcount by the end of 2015, with a goal of generating $1.5 billion of annual savings and a 15-point increase in adjusted operating margin by 2018. So far, the company's adjusted operating margin has increased from 38% in 2013 to 48% in 2015 and 55% in 1Q16. Management believes it is on a path to achieve 52-54% by 2018. In addition, the company's new next-generation bio-manufacturing facility is on track. The facility is expected to increase bulk production capabilities at a quarter of capital costs, 1/3 of operating costs and 2x speed vs. conventional facilities, resulting in an estimated cost reduction of 60%+ per gram of protein.

Competitive threats confront any company and even more so for biotech and pharma companies as their products face patent expirations. Biosimilar products are newer to the marketplace and the regulatory pathway is still evolving, with questions of interchangeability with the branded drug still progressing. Biologics are scientifically more challenging than small molecule generic development, more costly to develop and require high-quality complex manufacturing. Price discounting to date has been substantially less than small molecule generics, but may vary over the longer-term. As such, we look to acquire shares at a reasonable estimate of the company's base business without giving much credit to the pipeline. We believe this provides downside protection for the competitive threats while providing opportunity for upside given the growing pipeline. We took advantage of volatility during the quarter to acquire shares of Amgen common at around a 25% discount to our estimate of NAV.



From Third Avenue Value Fund's third quarter 2016 letter.



Check out Third Avenue Management,Martin Whitman latest stock trades

Top Ranked Articles about Amgen Inc

FDA Accepts Amgen's Biologics License Application for Aimovig The target action date is in May 2018
Amgen Inc. (NASDAQ:AMGN) announced July 20 the U.S. Food and Drug Administration will review its Biologics License Application for Aimovig.  Read more...
FDA Accepts Biologics License Application For Aimovig™ (erenumab)
Amgen Announces Webcast of 2017 Second Quarter Financial Results
Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation
FDA Requires Amgen to Update Marketing Application for Evenity The new submission must include data from several studies
Amgen Inc. (NASDAQ:AMGN) announced July 17 it has received a response from the U.S. Food and Drug Administration in regard to its Biologics License Application (BLA) for Evenity.  Read more...
Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US
Amgen Applies to Have Kyprolis' Label Updated New data indicate Kyprolis increases overall survival benefit by 7.6 months
Amgen Inc. (NASDAQ:AMGNinformed the stock market through the PRNewswire Friday that it has filed two new applications for Kyprolis, the brand name under which Amgen markets carfilzomib, a selective proteasome inhibitor acting anti-cancer drug, with the Food and Drug Administration and the European Medicines Agency. Read more...
Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label
Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)
Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma

Ratios

vs
industry
vs
history
PE Ratio 17.08
AMGN's PE Ratio is ranked higher than
78% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. AMGN: 17.08 )
Ranked among companies with meaningful PE Ratio only.
AMGN' s PE Ratio Range Over the Past 10 Years
Min: 10.4  Med: 16.15 Max: 30.95
Current: 17.08
10.4
30.95
Forward PE Ratio 14.41
AMGN's Forward PE Ratio is ranked higher than
73% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. AMGN: 14.41 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 17.08
AMGN's PE Ratio without NRI is ranked higher than
80% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. AMGN: 17.08 )
Ranked among companies with meaningful PE Ratio without NRI only.
AMGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.4  Med: 16.15 Max: 30.95
Current: 17.08
10.4
30.95
Price-to-Owner-Earnings 13.41
AMGN's Price-to-Owner-Earnings is ranked higher than
76% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. AMGN: 13.41 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AMGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.72  Med: 13.19 Max: 29.05
Current: 13.41
9.72
29.05
PB Ratio 4.33
AMGN's PB Ratio is ranked lower than
51% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. AMGN: 4.33 )
Ranked among companies with meaningful PB Ratio only.
AMGN' s PB Ratio Range Over the Past 10 Years
Min: 1.8  Med: 3.56 Max: 5.02
Current: 4.33
1.8
5.02
PS Ratio 5.88
AMGN's PS Ratio is ranked higher than
69% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. AMGN: 5.88 )
Ranked among companies with meaningful PS Ratio only.
AMGN' s PS Ratio Range Over the Past 10 Years
Min: 3.01  Med: 4.34 Max: 6.64
Current: 5.88
3.01
6.64
Price-to-Free-Cash-Flow 13.51
AMGN's Price-to-Free-Cash-Flow is ranked higher than
75% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. AMGN: 13.51 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.79  Med: 12.85 Max: 21.73
Current: 13.51
8.79
21.73
Price-to-Operating-Cash-Flow 12.45
AMGN's Price-to-Operating-Cash-Flow is ranked higher than
77% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. AMGN: 12.45 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.25  Med: 11.55 Max: 17.29
Current: 12.45
7.25
17.29
EV-to-EBIT 12.84
AMGN's EV-to-EBIT is ranked higher than
70% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. AMGN: 12.84 )
Ranked among companies with meaningful EV-to-EBIT only.
AMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.4  Med: 12.9 Max: 22.6
Current: 12.84
7.4
22.6
EV-to-EBITDA 10.60
AMGN's EV-to-EBITDA is ranked higher than
73% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AMGN: 10.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 10.5 Max: 18.2
Current: 10.6
6.2
18.2
PEG Ratio 0.84
AMGN's PEG Ratio is ranked higher than
79% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. AMGN: 0.84 )
Ranked among companies with meaningful PEG Ratio only.
AMGN' s PEG Ratio Range Over the Past 10 Years
Min: 0.18  Med: 1 Max: 3.03
Current: 0.84
0.18
3.03
Shiller PE Ratio 28.27
AMGN's Shiller PE Ratio is ranked higher than
76% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. AMGN: 28.27 )
Ranked among companies with meaningful Shiller PE Ratio only.
AMGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.24  Med: 26.89 Max: 57.65
Current: 28.27
17.24
57.65
Current Ratio 4.41
AMGN's Current Ratio is ranked higher than
52% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AMGN: 4.41 )
Ranked among companies with meaningful Current Ratio only.
AMGN' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 3.02 Max: 9.3
Current: 4.41
1.31
9.3
Quick Ratio 4.14
AMGN's Quick Ratio is ranked higher than
53% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. AMGN: 4.14 )
Ranked among companies with meaningful Quick Ratio only.
AMGN' s Quick Ratio Range Over the Past 10 Years
Min: 1.17  Med: 2.68 Max: 9.22
Current: 4.14
1.17
9.22
Days Inventory 238.75
AMGN's Days Inventory is ranked lower than
79% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. AMGN: 238.75 )
Ranked among companies with meaningful Days Inventory only.
AMGN' s Days Inventory Range Over the Past 10 Years
Min: 219.41  Med: 300.96 Max: 374.86
Current: 238.75
219.41
374.86
Days Sales Outstanding 51.71
AMGN's Days Sales Outstanding is ranked higher than
62% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. AMGN: 51.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.32  Med: 52.25 Max: 67.84
Current: 51.71
46.32
67.84
Days Payable 79.52
AMGN's Days Payable is ranked higher than
64% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. AMGN: 79.52 )
Ranked among companies with meaningful Days Payable only.
AMGN' s Days Payable Range Over the Past 10 Years
Min: 54.15  Med: 84.59 Max: 117.72
Current: 79.52
54.15
117.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.39
AMGN's Dividend Yield % is ranked higher than
82% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. AMGN: 2.39 )
Ranked among companies with meaningful Dividend Yield % only.
AMGN' s Dividend Yield % Range Over the Past 10 Years
Min: 0.48  Med: 1.67 Max: 2.8
Current: 2.39
0.48
2.8
Dividend Payout Ratio 0.39
AMGN's Dividend Payout Ratio is ranked higher than
52% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. AMGN: 0.39 )
Ranked among companies with meaningful Dividend Payout Ratio only.
AMGN' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.32 Max: 0.39
Current: 0.39
0.14
0.39
3-Year Dividend Growth Rate 28.60
AMGN's 3-Year Dividend Growth Rate is ranked higher than
82% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. AMGN: 28.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
AMGN' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 63.3
Current: 28.6
0
63.3
Forward Dividend Yield % 2.55
AMGN's Forward Dividend Yield % is ranked higher than
84% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.26 vs. AMGN: 2.55 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 14.14
AMGN's 5-Year Yield-on-Cost % is ranked higher than
97% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. AMGN: 14.14 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AMGN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.84  Med: 9.88 Max: 16.57
Current: 14.14
2.84
16.57
3-Year Average Share Buyback Ratio 0.70
AMGN's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. AMGN: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.1  Med: 0.9 Max: 8.7
Current: 0.7
-10.1
8.7

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 22.26
AMGN's Price-to-Tangible-Book is ranked lower than
91% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. AMGN: 22.26 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AMGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.85  Med: 12.03 Max: 150.81
Current: 22.26
3.85
150.81
Price-to-Intrinsic-Value-Projected-FCF 1.02
AMGN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
89% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. AMGN: 1.02 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.95 Max: 9.49
Current: 1.02
0.59
9.49
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.89
AMGN's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
77% of the 26 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. AMGN: 0.89 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.35
AMGN's Price-to-Median-PS-Value is ranked lower than
69% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. AMGN: 1.35 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.72  Med: 1.45 Max: 5.17
Current: 1.35
0.72
5.17
Price-to-Peter-Lynch-Fair-Value 0.90
AMGN's Price-to-Peter-Lynch-Fair-Value is ranked higher than
84% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. AMGN: 0.90 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AMGN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.58  Med: 1.21 Max: 3.33
Current: 0.9
0.58
3.33
Price-to-Graham-Number 4.11
AMGN's Price-to-Graham-Number is ranked lower than
67% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. AMGN: 4.11 )
Ranked among companies with meaningful Price-to-Graham-Number only.
AMGN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.52  Med: 3.75 Max: 23.03
Current: 4.11
1.52
23.03
Earnings Yield (Greenblatt) % 7.79
AMGN's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. AMGN: 7.79 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.4  Med: 7.7 Max: 13.6
Current: 7.79
4.4
13.6
Forward Rate of Return (Yacktman) % 24.43
AMGN's Forward Rate of Return (Yacktman) % is ranked higher than
71% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. AMGN: 24.43 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AMGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3  Med: 20.2 Max: 95.7
Current: 24.43
3
95.7

More Statistics

Revenue (TTM) (Mil) $22,928.00
EPS (TTM) $ 10.55
Beta1.76
Short Percentage of Float1.05%
52-Week Range $133.64 - 184.21
Shares Outstanding (Mil)735.40

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 22,689 22,586 22,444
EPS ($) 12.24 12.68 12.59
EPS without NRI ($) 12.24 12.68 12.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
2.82%
Dividends per Share ($) 4.61 5.15 5.62
» More Articles for AMGN

Headlines

Articles On GuruFocus.com
FDA Accepts Amgen's Biologics License Application for Aimovig Jul 21 2017 
FDA Accepts Biologics License Application For Aimovig™ (erenumab) Jul 20 2017 
Amgen Announces Webcast of 2017 Second Quarter Financial Results Jul 20 2017 
Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation Jul 18 2017 
FDA Requires Amgen to Update Marketing Application for Evenity Jul 17 2017 
Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US Jul 16 2017 
Amgen Applies to Have Kyprolis' Label Updated Jul 14 2017 
Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS Jul 14 2017 
Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimila Jul 13 2017 
Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival Jul 12 2017 

More From Other Websites
3 Stocks That Are Absurdly Cheap Right Now Jul 23 2017
[$$] Clinical Development News, July 17-21 Jul 21 2017
FDA Accepts Amgen's Biologics License Application for Aimovig Jul 21 2017
Will Gilead Beat 2Q Earnings? Perhaps…But Does It Matter? Jul 21 2017
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards? Jul 21 2017
3 Dividend Stocks That Thrive in Market Crashes Jul 21 2017
FDA Accepts Biologics License Application For Aimovig™ (erenumab) Jul 20 2017
Amgen Announces Webcast of 2017 Second Quarter Financial Results Jul 20 2017
Biotech Stocks On Verge Of Next Major Move Up Jul 19 2017
Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs Jul 19 2017
3 Dividend Stocks That Thrive in Both Bull and Bear Markets Jul 19 2017
Poor test results for Roche cloud growth prospects Jul 19 2017
Which Biotech Earnings Will Outperform? Jul 18 2017
Colorado biotech makes deal with industry giant Jul 18 2017
Ligand Signs Agreement with Amgen, Grants Rights to Captisol Jul 18 2017
Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation Jul 18 2017
Featured Company News – Amgen Submits Regulatory Applications in US, Europe to Include Overall... Jul 18 2017
Amgen FDA Letter Isn't A Surprise (Or A Concern), Says Jefferies Jul 17 2017
Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA Jul 17 2017
Amgen And UCB Provide Update On Regulatory Status Of EVENITY™ (romosozumab) In The US Jul 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}